Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol and Gadolinium MRI in Brain Tumors
NCT00659126Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Nov 2006
- Primary completion
- Dec 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ferumoxytol in primary brain neoplasm and brain neoplasm, sponsored by OHSU Knight Cancer Institute. Primary endpoint: Contrast to Noise Ratio for T1-weighted MRI Signal at Day 1. Started Nov 2006; status: terminated.
02
Drugs
ferumoxytol
03
Conditions
primary brain neoplasmbrain neoplasm
Beyond the preview
Go deeper on NCT00659126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00659126.